Ketamine therapy provider HOPE Therapeutics announced it plans to acquire five ketamine clinics and reach $100 million in annual revenue in less than a year. HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals (Nasdaq: NRXP), announced on Monday that it has secured $30 million in debt to finance the acquisitions. The company is apparently targeting five […]